Oncobiologics to Present at the World Biosimilar Congress 2017

Tuesday, May 9, 2017 1:01 PM UTC

CRANBURY, N.J., May 09, 2017 -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan, Ph.D., Chairman and Chief Executive Officer of Oncobiologics, will participate and present at the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.

Event: The World Biosimilar Congress 2017
Presentation Date: May 23-24, 2017
Location: Hilton San Diego Resort and Spa, San Diego, CA

Dr. Mohan will present on “Production efficiency: Streamlining both the development and manufacturing process,” on May 23^rd at 3:20 p.m. On the same day, Dr. Mohan will also participate in a panel discussion on Intellectual Property at 5:00 p.m. On May 24^th at noon, he will moderate a roundtable discussion of industry executives on “Achieving required data for regulatory and commercial approvals.”

World Biosimilar Congress 2017

To learn more about the World Biosimilar Congress and to register for the conference please visit http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm

About Oncobiologics, Inc. and its BioSymphony™ Platform

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com

CONTACTS:

Oncobiologics:                         
Lawrence A. Kenyon
Chief Financial Officer
[email protected]

Media & Investors:                 
Alex Fudukidis
Russo Partners, LLC
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Oncobiologics to Present at the World Biosimilar Congress 2017

Editor's Picks

Welcome to EconoTimes